

Hypersensitivity reactions related to oxaliplatin (OHP)

G Brandi^{*1}, MA Pantaleo¹, C Galli², A Falcone², A Antonuzzo², P Mordenti¹, MC Di Marco¹ and G Biasco

¹Institute of Haematology and Medical Oncology 'L. & A. Seragnoli', University of Bologna, Policlinico Sant'Orsola, Via Massarenti 9, 40138 Bologna, Italy;

²Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno Viale Alfieri 36, 58128 Livorno, Italy

Patients treated with platinum compounds are subject to hypersensitivity reactions. Our study has highlighted the reactions related to oxaliplatin (OHP) infusion. One hundred and twenty-four patients affected by advanced colorectal cancer were treated with different schedules containing OHP, at the Institute of Haematology and Medical Oncology 'L. and A. Seragnoli' of Bologna and at the Medical Oncology Division of Livorno Hospital. Seventeen patients (13%) showed hypersensitivity reactions after a few minutes from the start of the OHP infusion. Usually, these reactions were seen after 2–17 exposures to OHP (Mean \pm s.e.: 9.4 ± 1.07). No patient experienced allergic reactions at his/her first OHP infusion. Eight patients developed a mild reaction consisting of flushing and swelling of the face and hands, itching, sweating and lachrymation. The remaining nine patients showed a moderate–severe reaction with dyspnoea, wheezing, laryngospasm, psycho-motor agitation, tachycardia, precordial pain, diffuse erythema, itching and sweating. Six patients out of 17 were re-exposed to the drug with premedication of steroids and all except one developed the hypersensitivity reaction again. The cumulative dose, the time of exposure to OHP and the clinical features are variable and unpredictable. The risk of developing hypersensitivity reactions in patients treated with a short infusion of OHP cannot be underestimated.

British Journal of Cancer (2003) 89, 477–481. doi:10.1038/sj.bjc.6601155 www.bjcancer.com

© 2003 Cancer Research UK

Keywords: Hypersensitivity reaction; platinum compound; colorectal cancer; chemotherapy

Oxaliplatin (OHP) is the most recent platinum compound entering the clinical practice. It is an alkylating agent on DNA and forms DACH-platinum DNA adducts more hydrophobic than those formed by cisplatin (CDDP) and carboplatin (CBDCA). It is effective in advanced colorectal cancer both as a first-line therapy and in 5-fluorouracil (5-FU) refractory patients (Bertheault-Cvitkovic *et al*, 1996; De Gramont *et al*, 1997; Andre' *et al*, 1999; Maindrault-Goebel *et al*, 1999).

OHP is less nephro-toxic than CDDP and less mielotoxic than CBDCA (Misset 1998). The most characteristic and dose-limiting toxicity of OHP is sensory neuropathy, which is dose cumulative and schedule related. It is clinically characterised by a transient acute cold-related dysaesthesias, sometimes pain-associated, or with cramps and functional failure, although it is generally reversible (Caussanel *et al*, 1990, Misset, 1998). Hypersensitivity reactions to oxaliplatin have been described only sporadically.

For other platinum compounds, this kind of reaction is well known (Cleare *et al*, 1976; Wiesenfeld *et al*, 1979; Planner *et al*, 1991; Morgan *et al*, 1994; Weideman *et al*, 1994; Shleback *et al*, 1995; Markman *et al*, 1999; Özgüroglu *et al*, 1999). On data sheets of OHP, these clinical features are not stressed. In fact, only the main severe form of hypersensitivity, that is to say anaphylaxis, is reported in 0.5% of patients treated. This reaction is clinically characterised by laryngospasm and wheezing and immunologically linked to the release of histamine and other vaso-active substances.

As a result of the increasing use of OHP in colorectal cancer, we have found frequent hypersensitivity reactions. In this study, we report the epidemiological and clinical features of these reactions, as well as their management.

MATERIALS AND METHODS

From February 1999 to February 2002 at the Institute of Haematology and Medical Oncology 'L. and A. Seragnoli' of Bologna and at the Medical Oncology Division of Livorno, 124 outpatients with advanced colorectal cancer were treated with OHP-based therapies. Eighty-four out of 124 patients (67.7%) received OHP as a first-line treatment. Fifty-five patients (44.3%) were treated with a FOLFOX-4 regimen (Andre' *et al*, 1999; De Gramont *et al*, 2000), 34 patients (27.4%) with FOLFOX-3 regimen (De Gramont *et al*, 1999), 30 patients (24.1%) with the association of OHP/CPT-11/c.i.5-FU/FA regimen (Falcone *et al*, 2002), three patients (2.4%) with OHP alone (Diaz-Rubio *et al*, 1998) and two patients (1.6%) with OHP/Raltitrexed regimen (Seitz *et al*, 1999). All patients received a standard antiemetic treatment with ondansetron 8 mg by a i.v. administration before chemotherapy. We did not use dexamethasone in this population.

Major sites of metastases were the liver, lungs and peritoneum. Among these patients, 17 out of 124 (13.7%) reported a hypersensitivity reaction attributable to OHP. There were eight males and nine female patients, with a mean age of 60.3 years (range 37–76). In 11 out of 17 patients with hypersensitivity reaction, OHP was administered in first-line chemotherapy.

*Correspondence: Dr G Brandi; E-mail: gbrandi@med.unibo.it

Received 8 July 2002; revised 22 April 2003; accepted 25 May 2003

RESULTS

Results are shown in Table 1. The reaction occurs after a mean \pm s.e. = 9.4 ± 1.07 infusions of chemotherapy (range 2–17). Only two patients experienced early hypersensitivity at the second and third infusion, respectively.

On average, there were 217.7 ± 32.5 days (mean \pm s.e.) (range 74–575) between the first exposure to OHP and the reaction.

Eight out of 124 (6.5%) patients reported only erythema and itching of the palms and flushing of the face and hands after the beginning of OHP infusion. Nine out of 124 (7.3%) patients developed a more severe reaction with dyspnoea, wheezing,

Table 1 Patients with hypersensitivity reactions

Case	Sites of metastases	Chemotherapy regimen	Infusion number at reaction	Total dose of OHP (mg)	Clinical features of reaction	Length of reaction (min)	Treatment of reaction	Re-exposure to OHP with premedication and outcome
1	Lung	FOLFOX-4	3	382	Bronchospasm	7 days	Hospitalisation/high dose of steroid	No
2	Peritoneum	FOLFOX-4	14	2100	Laryngospasm Dyspnoea Bronchospasm Dyspnoea Hand oedema Erythema	60	Oxygen Steroids Antihistaminic	No
3	Liver	Oxaliplatin	10	2070	Bronchospasm Dyspnoea Hypotension	50	Steroids	No
4	Liver Lung	FOLFOX-3	17	2271	Dyspnoea Hand, face oedema Erythema, itching Psychomotor agitation	5–10	Steroids Antihistaminic	Yes, with reaction
5	Peritoneum	Oxaliplatin	2	360	Dyspnoea Laryngospasm	120	Steroids Antihistaminic	No
6	Liver	Irinotecan Oxaliplatin Fluorouracil Folinic acid	11	1620	Dyspnoea Eye oedema Face erythema Itching Sweating	15–20	Steroids Antihistaminic	No
7	Liver Lung	FOLFOX-3	17	2720	Dyspnoea Oedema Erythema Sweating Lachrymation	15–20	Steroids Antihistaminic	Yes, with reaction
8	Liver	FOLFOX-4	6	900	Dyspnoea Erythema Itching Mouth oedema	30	Steroids Antihistaminic	No
9	Liver Lung	FOLFOX-4	8	1120	Dyspnoea Hand, face erythema	60	Steroids Antihistaminic	No
10	Liver	FOLFOX-4	8	1360	Erythema, Tachycardia Precordial pain Pruritus	15–20	Steroids Antihistaminic	No
11	Peritoneum	FOLFOX-4	9	630	Hand oedema, Hand genital itching Hand, face erythema	20	Antihistaminic	Yes, without reaction
12	Peritoneum	FOLFOX-4	5	940	Hand face erythema Hand oedema Hand itching	20–30	Antihistaminic	No
13	Liver Peritoneum	Irinotecan Oxaliplatin Fluorouracil Folinic acid	14	2600	Itching Sweating Lachrymation Face oedema, Face erythema	15–20	Steroids Antihistaminic	Yes, with reaction
14	Liver	FOLFOX-4	7	1040	Face, chest erythema Itching	120	Steroids Antihistaminic	Yes, with reaction
15	Liver Peritoneum	FOLFOX-4	13	1705	Face, chest erythema Shiver without fever Tremor	50	Steroids Antihistaminic	No
16	Diaphragm	FOLFOX-4	8	1080	Arms, chest erythema With pomphoid reaction	50	Steroids	Yes, with reaction
17	Peritoneum	FOLFOX-3	9	1377	Sweating Erythema Hypotension Nausea	15–20	Steroids	No

Table 2 Number of reactions according to the regimen

Chemotherapy regimen	No. of patients	No. of reactions	% reaction according to the regimen	Mean no. of infusions at the reaction onset
FOLFOX-4	55	10	18.1	8.1
FOLFOX-3	34	3	8.8	14.3
Irinotecan Oxaliplatin	30	2	6.6	12.5
Fuorouracil Folinic acid Oxaliplatin	3	2	66.6	6

laryngospasm, psico-motor agitation, tachycardia, precordial pain, diffuse erythema, itching and sweating. Only two patients experienced the symptoms at the end of the infusion, while the others developed the reaction between 10 to 15 min from the start of OHP infusion. All patients showing hypersensitivity were treated with steroids, many of them in association with antihistaminic drugs. The symptoms disappeared within half an hour to 2 h after stopping the OHP infusion and the beginning of the antiallergic therapy. One patient required hospitalisation for dyspnoea that disappeared in a few days.

Once the reaction had disappeared, nine patients continued the scheduled drug infusions, in particular 5-fluorouracil (5-FU) and Folinic acid, without any additional problem.

The percentage of reaction is different according to the chemotherapy regimens employed: 66.6% for OHP alone, 18.1% for FOLFOX-4 regimen, 8.8% for FOLFOX-3 regimen and 6.6% for OHP/CPT-11/c.i.5-FU/FA regimen (Table 2).

Three patients developed the reaction to the first chemotherapy treatment after a long period of rest. The total administered doses of OHP in patients developing the reaction are reported in Table 1. The cumulative dose of OHP was $1428 \text{ mg} \pm 176.7$ (mean \pm s.e.) (range 360–2720 mg).

Six out of 17 patients with hypersensitivity reactions were successively re-exposed to OHP chemotherapy after premedication with steroids and antihistaminic drugs. Five of these six patients developed the same symptoms again, while one patient had no further reaction.

DISCUSSION

Hypersensitivity reactions to platinum compounds are a well-known phenomena (Weiss, 1992). In the 1950s, literature reported the capacity of platinum salts to induce bronchial asthma among platinum-refinery workers (Hunter *et al*, 1945). It is not surprising that after the introduction of platinum compounds into chemotherapy, their association with type I hypersensitivity reactions was confirmed (Cleare *et al*, 1976). These reactions were first described for CDDP with a 5–20% incidence (Wiesenfeld *et al*, 1979; Shleback *et al*, 1995; Özgüroglu *et al*, 1999), and evidence regarding similar reactions for CBDCA are also available (Planner *et al*, 1991; Morgan *et al*, 1994; Weideman *et al*, 1994; Markman *et al*, 1999).

This kind of toxicity has been sporadically reported in clinical trials focusing on the effectiveness of OHP in chemotherapy or described as case reports (Machover *et al*, 1996; Diaz Rubio *et al*, 1998; Tournigand *et al*, 1998; Larzilliere *et al*, 1999; Medioni *et al*, 1999; De Gramont *et al*, 2000; Dold *et al*, 2002; Monnet *et al*, 2002).

Our results support the assumption that this side effect should not be underestimated. More than 13% of OHP-treated patients developed hypersensitivity reaction. This phenomenon is not well known, probably because OHP entered clinical practice only a few years ago. Moreover, according to our experience, the reactions generally develop after about 9–10 infusions. The relationship between the hypersensitivity reaction and OHP is supported by the following evidence. First, the symptoms developed a few minutes

after starting the OHP infusion; secondly, the patients re-exposed to successive OHP administration developed a similar reaction; thirdly, two patients developed a reaction after monochemotherapy OHP infusion; finally, in patients treated with OHP/CPT-11/c.i. 5-FU/FA regimen, the reaction could be confused with a cholinergic syndrome due to CPT-11, but the responsibility of CPT-11 can be excluded since the re-exposure to CPT-11/c.i. 5-FU/FA without OHP was not able to provoke the hypersensitivity reaction.

The pathophysiology of hypersensitivity reactions is not clear, but the finding that almost all patients developed the reaction after multiple infusions of treatment suggests the need to be sensitised during previous cycles. Symptoms usually develop early after the start of the infusion and have been described to a type I hypersensitivity Ig-E-mediated reaction (Stahl *et al*, 2001).

A different hypothesis suggests that platinum salts could induce an oligo or polyclonal T-cells expansion. These compounds can act as a superantigen on the peripheral blood mononuclear cells, thus releasing a large amount of proinflammatory cytokines (IL-6, TNF α , γ interferon) (Santini *et al*, 2001). The other possible mechanism consists in binding the platinum salts to different peptides of major histocompatibility complex (MHC).

In fact, HLA phenotype is a significant determinant of occupational sensitisation to inhaled hapten of complex platinum salts and the strength of this association varies according to the intensity of exposure (Newman Taylor *et al*, 1999).

Furthermore, the relationship between hypersensitivity reactions and HLA-haplotype has been described for other drugs (Hetherington *et al*, 2002). Additional factors are deemed to be necessary to the immune system for developing the reaction after several infusions.

Apart from hypersensitivity-related dyspnoea and wheezing, the lung may also be the target of a particular toxicity. A patient treated with OHP-5FU therapy developed severe dyspnoea. A bronchus alveolar lavage (BAL) and a lung biopsy diagnosed a diffuse alveolar damage that disappeared with steroid therapy (Trisolini *et al*, 2001).

In our experience, when a hypersensitivity reaction occurred, the infusion of OHP was immediately stopped and replaced by a saline infusion, an intravenous antihistaminic drug and a low-dose corticosteroids administration. In the case of more severe reactions (dyspnoea, sweating, bronchospasm, laryngospasm), we immediately administered a high dose of steroid. The steroid dose ranged between 100 and 1000 mg of hydrocortisone. After the reaction disappeared, the OHP infusion was not restarted and the decision to administer the other scheduled drugs was taken evaluating the clinical status of the patient after the reaction, the risk of additional toxicity and the clinical utility of the chemotherapy. In this way, about two-thirds of patients (11 patients) continued the infusion of other planned antitubercular drugs without any additional clinical problems.

In order to avoid further hypersensitivity problems in successive cycles, one can presumably explore a maximum prophylactic immunological blockage with a high dose of steroids and antihistaminic drugs for several days before the infusion of OHP, but the real benefit is uncertain because five out of six patients

treated with steroids and/or antihistaminic drugs immediately before re-exposure developed the same intensity of reaction.

Documented data suggest that OHP as a continuous 6-h infusion seems to decrease the risk of hypersensitivity reactions. Only one out of 100 (1%) patients treated with OHP as a 6-h infusion added to chronomodulated 5-FU-FA as a first-line treatment of advanced colorectal cancer developed hypersensitivity-like reactions (Giacchetti *et al*, 2000). When OHP is infused in a chronomodulated setting (as a 12-h infusion) or flat infusion for 5 days, these hypersensitivity reactions do not occur. In particular, 151 patients submitted to 1087 constant rate continuous infusion courses of OHP, and 491 patients submitted to 3106 chronomodulate OHP courses did not experience any hypersensitivity reactions (Caussanel *et al*, 1990; Levi *et al*, 1992, 1993, 1994b, 1997, 1999; Bertheault-Cvitkovic *et al*, 1996).

Therefore, the incapacity of these schedules to produce hypersensitivity might be due to a long time infusion rather than to failure of activation of the immune system (which presents a circadian rhythm) in a chronomodulated setting (Levi *et al*, 1994a).

Interestingly, five patients who developed hypersensitivity reactions to 2-h OHP infusion, when re-exposed to 6-h OHP infusion, did not show any symptoms (Maindrait-Goebel *et al*, 2001). The mechanism is still unclear, although it is supposed that the maximum concentration reached by the drug is lower in a longer time of infusion. Theoretically this situation might occur with increased hydration, but no data are available. In the adjuvant setting, the number of allergic reactions is different from the

advanced disease. In fact only 2% of the allergic, not already specified, reactions have been reported (De Gramont *et al*, 2002). The reason for this important difference is unclear.

It could be possible that the tumour releases factors able to make the immune system more sensitive, but no data are available.

In our study, neither the cumulative dose of OHP nor the lapse of time between the first exposition and the reaction are able to predict the hypersensitivity reaction. In our experience, the severity of clinical symptoms is variable and we cannot identify the patients at risk of developing the reaction or the factors indicating the patients where the reaction could be more severe. Particular attention is necessary when the lung is the target of reaction, because the re-exposure to OHP generally affects the same site with higher intensity. Special care is mandatory in patients receiving OHP for a long time and/or re-exposing to OHP after a pause.

In conclusion, a late hypersensitivity reaction seems a limiting toxicity of OHP administered in 2 h, and in patients previously affected it is advisable to avoid readministration of OHP with the same short schedule.

Literature data suggest that long-term OHP infusions are able to prevent the hypersensitivity reaction. The use of steroids does not seem useful in preventing hypersensitivity in patients having experienced previous reactions. On the contrary, long-term infusions, without dose decreasing, may prevent this reaction in patients previously affected, but a larger number of cases are required to provide definite responses on this matter.

REFERENCES

- Andre' T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Dupont-Andre G, De Gramont A (1999) Multicentric phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. *J Clin Oncol* **17**: 3560–3568
- Bertheault-Cvitkovic F, Jami A, Ithzaki M, Deprès Brummer P, Brienza R, Adam R, Kunstlinger F, Bismuth H, Misset JL, Levi F (1996) Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. *J Clin Oncol* **14**: 2950–2958
- Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathè Get (1990) Phase II trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. *J Natl Cancer Inst* **82**: 1046–1050
- Cleare MJ, Hughes EG, Jacob B, Pepys B (1976) Immediate (type I) allergic responses to platinum compounds. *Clin Allergy* **6**: 183–195
- De Gramont A, Boni C, Navarro M, Tarbenero J, Hickish T, Topham C, Bonetti A, Clingan P, Dvidson N, Mounedji-Boudiaf L, André T (2002) Oxaliplatin/5-FU/LV in adjuvant colon cancer: safety results of the international randomized MOSAIC Trial. Abstract 525, ASCO 2002
- De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Corte-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hender D, De Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. *J Clin Oncol* **18**: 2938–2947
- De Gramont A, Maindrait-Goebel F, Louvet C, Andre T, Carola E, Gilles-Amar V, Mabro M, Izrael V, Krulik M (1999) Evaluation of oxaliplatin dose-intensity with the bimonthly 48 h leucovorin (LV) and 5-fluorouracil (5FU) regimens (FOLFOX) in pretreated metastatic colorectal cancer. Proceedings ASCO 1999
- De Gramont A, Vignoud J, Tournigand C, Louvet C, Andr T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M (1997) Oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. *Eur J Cancer* **33**: 214–219
- Diaz-Rubio E, Sastre J, Zaniboni A, La bianca R, Cortès-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. *Ann Oncol* **9**: 105–108
- Dold F, Hoey D, Carbery M, Musket A, Friedberg V, Mitchell E (2002) Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin. Abstract 1478, ASCO 2002
- Falcone A, Masi G, Allegrini G, Dansei R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P (2002) Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. *J Clin Oncol* **20**: 4006–4014
- Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letornou Y, Coudert B, Bertheault-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. *J Clin Oncol* **18**: 136–147
- Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowan C, Thurmond LM, Roses AD (2002) Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. *Lancet* **359**: 1121–1122
- Hunter D, Milton R, Perry KMA (1945) Asthma caused by complex salts of platinum. *Br J Ind Med* **2**: 92–98
- Larzilliere I, Brandissou S, Breton P, Lingoungou A, Gargot D, Romain JP, Harnois C (1999) Anaphylactic reaction to oxaliplatin: a case-report. *AJG* **94**: 3387–3388
- Levi F, Bourin P, Deprès-Brummer P, Adam R (1994a) Chronobiology of the immune system. Implication for the delivery of therapeutic agents. *Clin Immunother* **2**: 53–64
- Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzhaki M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorp-Declère A, Jasmin C, Bismuth H, Reinberg A (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folic acid, and oxaliplatin using an ambulatory multi-channel programmable pump. *Cancer* **69**: 893–900
- Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Deprès-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S, Kurstilnger F, Gastiaburu J, Misset JL (1993) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. *Eur J Cancer* **29**: 1280–1284
- Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotsrski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C (1999) A multicentric evaluation of intensified, ambulatory, chronomodulated chemotherapy with

- oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal cancer. *Cancer* **85**: 2532–2540
- Levi F, Zidani R, Misset JL (1997) Randomised multicentric trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. *Lancet* **350**: 681–686
- Levi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, Iacobelli S, Adam R, Kunstlinger F, Gastaburu J, Bismuth H, Jasmin C, Misset JL (1994b) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomised multi-institutional trial. *J Natl Cancer Inst* **86**: 1608–1617
- Machover D, Diaz-Rubio E, De Gramont A, Schilf A, Gastiburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sstrel J, Seitz JF, Ychou M (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. *Ann Oncol* **7**: 95–98
- Maindrault-Goebel F, De Gramont A, Louvet C, André T, Carola E, Mabro M, Atru P, Gilles V, Izrael V, Krulik M, for the Oncology Multidisciplinary Research Group (GERCOR 2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second line therapy for metastatic colorectal cancer (FOLFOX 7). *Eur J Cancer* **37**: 1000–1005
- Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML, Giller-Amar V, Izrael V, Krulik M, De Gramont A (1999) Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimens as second-line therapy for metastatic colorectal cancer (FOLFOX-6). *Eur J Cancer* **35**: 1338–1342
- Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belison J (1999) Clinical features of hypersensitivity reactions to carboplatin. *J Clin Oncol* **17**: 1141–1145
- Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL (1999) Anaphylaxis after oxaliplatin. *Ann Oncol* **10**: 610
- Misset JL (1998) Oxaliplatin in practice. *Br J Cancer* **77** (Suppl 4): 4–7
- Monnet I, De Cremoux H, Soulie P, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E (2002) Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicentric phase II study. *Ann Oncol* **13**: 103–107
- Morgan JS, Adams M, Mason MD (1994) Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. *Eur J Cancer* **30A** (8): 1205–1206
- Newman Taylor AJ, Cullinan P, Lympny PA, Harris JM, Dowdeswell RJ, DuBois RM (1999) Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. *Am J Resp Crit Care Med* **160**: 435–438
- Özgüroglu M, Demir G, Demirelli F, Mandel NM (1999) Anaphylaxis from intraperitoneal infusion of cisplatin. *Am J Clin Oncol* **22**: 172–173
- Planner RS, Weerasiri T, Timmins D, Grant P (1991) Hypersensitivity reaction to carboplatin. *J Natl Cancer* **83** (23): 1763–1764
- Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Dicuonzo G, La Bianca R (2001) Idiosyncratic reaction after oxaliplatin infusion. *Ann Oncol* **12**: 132–133
- Seitz JF, Douillard JY, Paillot B (1999) Tomudex (raltitrexed) plus oxaliplatin as first line chemotherapy in metastatic colorectal cancer (MCR): a promising combination. Abstract 257, ASCO 1999
- Shleback AA, Clark PI, Green JA (1995) Hypersensitivity and cross-reactivity to cisplatin and analogues. *Cancer Chemother Pharmacol* **35**: 349–351
- Stahl M, Köster W, Wilke H (2001) Reaction after oxaliplatin – prevention with corticosteroids? *Ann Oncol* **12**: 874
- Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M, Falcone F, Poletti V (2001) Acute lung injury associated with 5-fluorouracil and oxaliplatin combined chemotherapy. *Eur Respir J* **18**: 243–245
- Tournigand C, Maindrault-Goebel, Louvet C, De Gramont A, Krulik M (1998) Severe anaphylactic reactions of oxaliplatin. *Eur J Cancer* **34**: 1297–1298
- Weideman B, Mülleneisen N, Bojko P, Niederle N (1994) Hypersensitivity reactions to carboplatin. *Cancer* **73**: 2218–2222
- Wiesenfeld M, Reiders E, Corder M, Yoo IJ, Lovett J (1979) Successful re-treatment with cis-dichlorodiammineplatinum (II) after apparent allergic reactions. *Cancer Treat Rep* **63**: 219–221
- Weiss RB (1992) Hypersensitivity reactions. *Semin Oncol* **19**: 458–477